[go: up one dir, main page]

DK1531798T3 - Pulmonal frigørelse af Levodopa - Google Patents

Pulmonal frigørelse af Levodopa

Info

Publication number
DK1531798T3
DK1531798T3 DK03714302.1T DK03714302T DK1531798T3 DK 1531798 T3 DK1531798 T3 DK 1531798T3 DK 03714302 T DK03714302 T DK 03714302T DK 1531798 T3 DK1531798 T3 DK 1531798T3
Authority
DK
Denmark
Prior art keywords
levodopa
pulmonary release
pulmonary
release
Prior art date
Application number
DK03714302.1T
Other languages
English (en)
Inventor
Blair Jackson
Raymond T Bartas
David J Bennett
Dwaine F Emerich
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Application granted granted Critical
Publication of DK1531798T3 publication Critical patent/DK1531798T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK03714302.1T 2002-03-20 2003-03-19 Pulmonal frigørelse af Levodopa DK1531798T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36647102P 2002-03-20 2002-03-20
PCT/US2003/008659 WO2003079992A2 (en) 2002-03-20 2003-03-19 Pulmonary delivery for levodopa

Publications (1)

Publication Number Publication Date
DK1531798T3 true DK1531798T3 (da) 2012-08-13

Family

ID=28454804

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03714302.1T DK1531798T3 (da) 2002-03-20 2003-03-19 Pulmonal frigørelse af Levodopa
DK13161929.8T DK2630954T3 (da) 2002-03-20 2003-03-19 Pulmonal indgivelse af levodopa

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13161929.8T DK2630954T3 (da) 2002-03-20 2003-03-19 Pulmonal indgivelse af levodopa

Country Status (13)

Country Link
US (7) US7879358B2 (da)
EP (3) EP2630954B1 (da)
JP (1) JP4384503B2 (da)
AU (1) AU2003218307B8 (da)
CA (1) CA2478980C (da)
CY (1) CY1118517T1 (da)
DK (2) DK1531798T3 (da)
ES (3) ES2389156T3 (da)
HU (1) HUE031167T2 (da)
LT (1) LT2630954T (da)
PT (3) PT1531798E (da)
SI (1) SI2630954T1 (da)
WO (1) WO2003079992A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1531798T3 (da) * 2002-03-20 2012-08-13 Civitas Therapeutics Inc Pulmonal frigørelse af Levodopa
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
JPWO2006095788A1 (ja) * 2005-03-09 2008-08-14 小野薬品工業株式会社 粒子およびその粒子を含有する製剤
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
AU2010229668C1 (en) 2009-03-26 2016-09-15 Pulmatrix Operating Co., Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2448571B1 (en) 2010-08-30 2013-06-12 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
EP2621484A1 (en) 2010-09-29 2013-08-07 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
EP2819672A1 (en) 2012-02-29 2015-01-07 Pulmatrix, Inc. Inhalable dry powders
HK1212257A1 (en) * 2012-10-22 2016-06-10 Civitas Therapeutics, Inc. Reducing inter-patient variability of levodopa plasma concentrations
ES2886529T3 (es) * 2012-10-22 2021-12-20 Civitas Therapeutics Inc Formulaciones de levodopa para el alivio rápido de la enfermedad de Parkinson
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
US20140150787A1 (en) 2012-12-04 2014-06-05 Civitas Therapeutics, Inc. Devices and methods for puncturing a capsule to release a powdered medicament therefrom
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
TWI589308B (zh) * 2014-03-25 2017-07-01 林信湧 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法
EP3134077A4 (en) * 2014-04-21 2017-12-20 Civitas Therapeutics, Inc. Rapid relief of motor fluctuations in parkinson's disease
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
CA2991108A1 (en) 2015-07-02 2017-01-05 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
EP3565700B1 (en) 2017-01-30 2024-05-15 GlobalMed, Inc. Heated respiratory hose assembly
CN112955134A (zh) * 2018-07-19 2021-06-11 英倍尔药业股份有限公司 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送
JP2019108379A (ja) * 2019-03-05 2019-07-04 サイヴィタス セラピューティックス，インコーポレイテッド パーキンソン病の運動症状変動の迅速な緩和
IT202000030437A1 (it) * 2020-12-10 2022-06-10 Zambon Spa Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo
US12005185B2 (en) * 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689643A (en) * 1971-01-27 1972-09-05 Abbott Lab Combination of l-dopa, 2-imino-5-phenyl-4-oxazolidinone and an aluminum or alkaline earth metal salt or base used to treat parkinson{40 s disease
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4511258A (en) 1983-03-25 1985-04-16 Koflo Corporation Static material mixing apparatus
JPS6122019A (ja) 1984-07-06 1986-01-30 Tomio Konno 吸入細胞活性薬品とその使用方法
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
EP0223831B1 (en) * 1985-05-22 1992-07-15 Liposome Technology, Inc. Liposome inhalation method and system
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US6048857A (en) * 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JPH05507090A (ja) 1990-05-08 1993-10-14 リポサーム　テクノロジー　インコーポレイテッド 直接噴霧乾燥された薬剤／脂質粉末組成物
US5166202A (en) * 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
JPH0697804A (ja) * 1991-01-08 1994-04-08 Nec Corp 論理回路
GB9101592D0 (en) 1991-01-24 1991-03-06 Glaxo Group Ltd Compositions
DK0533268T3 (da) * 1991-09-18 2001-12-03 Glaxo Group Ltd Benzanilidderivater som 5HT-1D antagonister
US5457100A (en) * 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5756071A (en) * 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5354885A (en) 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
DE69535897D1 (de) 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
CA2152684A1 (en) 1994-07-01 1996-01-02 Richard Anthony Henry Aerosol delivery of midazolam
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6103270A (en) * 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US6193954B1 (en) * 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
US5958902A (en) 1997-04-16 1999-09-28 Wisconsin Alumni Research Foundation Method and composition for treating sleep apnea
KR100883477B1 (ko) 1999-05-27 2009-02-16 아쿠스피어 인코포레이티드. 다공성 약물 매트릭스의 약제 조성물
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DK1531798T3 (da) * 2002-03-20 2012-08-13 Civitas Therapeutics Inc Pulmonal frigørelse af Levodopa
US10156302B1 (en) 2016-02-09 2018-12-18 Blox, Llc Mechanical electrical plumbing rack device

Also Published As

Publication number Publication date
WO2003079992A2 (en) 2003-10-02
ES2487816T3 (es) 2014-08-25
HUE031167T2 (hu) 2017-07-28
AU2003218307A1 (en) 2003-10-08
US20140105983A1 (en) 2014-04-17
US9155699B2 (en) 2015-10-13
PT2630954T (pt) 2017-01-05
US20040018989A1 (en) 2004-01-29
EP2630954B1 (en) 2016-10-05
US20130164349A1 (en) 2013-06-27
PT2494962E (pt) 2014-08-27
JP2006507218A (ja) 2006-03-02
US20180055800A1 (en) 2018-03-01
CA2478980A1 (en) 2003-10-02
DK2630954T3 (da) 2017-01-23
EP2494962A2 (en) 2012-09-05
WO2003079992A3 (en) 2005-03-31
ES2389156T3 (es) 2012-10-23
US8586093B2 (en) 2013-11-19
PT1531798E (pt) 2012-09-10
EP1531798A2 (en) 2005-05-25
EP1531798A4 (en) 2010-11-03
JP4384503B2 (ja) 2009-12-16
LT2630954T (lt) 2017-01-25
USRE43711E1 (en) 2012-10-02
CY1118517T1 (el) 2017-07-12
EP2494962A3 (en) 2013-01-16
ES2609482T3 (es) 2017-04-20
AU2003218307B8 (en) 2006-08-31
EP1531798B1 (en) 2012-06-06
US7879358B2 (en) 2011-02-01
EP2494962B1 (en) 2014-05-14
AU2003218307B2 (en) 2006-07-27
CA2478980C (en) 2008-07-15
US20160058727A1 (en) 2016-03-03
EP2630954A1 (en) 2013-08-28
US20110151008A1 (en) 2011-06-23
SI2630954T1 (sl) 2017-02-28
US8404276B2 (en) 2013-03-26

Similar Documents

Publication Publication Date Title
DK1531798T3 (da) Pulmonal frigørelse af Levodopa
DK2258716T3 (da) Multiple varianter af meningokokprotein nmb1870
DK2363114T3 (da) Opretholdt afgivelse af anti-infektionsmidler
DK1532474T3 (da) Markering af rørforforbindelser
NO20034075L (no) Utvidbar kopling
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1501508T3 (da) Inhibitorer af histondeatylase
DK3385267T3 (da) Syntese af boronestere og syreforbindelser
DK1438306T3 (da) Derivater af UK-2A
DK1778618T3 (da) Syntese af triethylentetraminer
DE50311783D1 (de) Pyridazinderivate
DE60322651D1 (de) Trockentoner
DE60335183D1 (de) Kamera
DK1470732T3 (da) Fremskaffelse af lokaliseringsinformation
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
IS2787B (is) Módafíníllyfjasamsetningar með breytta losun
DE50304987D1 (de) Webmaschine
DE50311980D1 (de) Weblitze
DE50202991D1 (de) Hochtemperaturfestes Klebemittel
NO20041999L (no) Viral inhibering med n-docosanol
DE60320725D1 (de) Webblatt
DK1611361T3 (da) Ekspansionsanker af metal
DE10394115D2 (de) Schabewärmetauscher
FI20020763A7 (fi) Kompraattoripiiri